Pasithea Therapeutics Corp. (KTTA) Research

Pasithea Therapeutics Corp. functions as a biotechnology firm dedicated to the discovery and advancement of novel therapeutic solutions for various psychiatric and neurological conditions. Beyond its research endeavors, the company also plans to establish and manage clinics specializing in depression treatment. These facilities are designed to offer business support, employing trained pharmacists to administer intravenous ketamine infusions. Founded in 2020, the corporation's primary operations are based in Miami Beach, Florida.

Market snapshot

Symbol
KTTA
Price
$0.50
Day change
-0.46%
Market cap
$3.7M
P/E ratio
-0.18x
52-week range
0.281-2.06
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$3.00

Peer companies

  • AIM ImmunoTech Inc. (AIM)
  • Cyclerion Therapeutics, Inc. (CYCN)
  • Impact BioMedical Inc. (IBO)
  • KALA BIO, Inc. (KALA)
  • NovaBay Pharmaceuticals, Inc. (NBY)
  • Polyrizon Ltd. (PLRZ)
  • Quoin Pharmaceuticals, Ltd. (QNRX)
  • Alaunos Therapeutics, Inc. (TCRT)

Recent insider activity

  • Marques Tiago — A-Award (1756069 shares) on 2026-05-01
  • STEINMAN LAWRENCE — A-Award (152783 shares) on 2026-05-01
  • Dumesnil Simon — A-Award (152783 shares) on 2026-05-01
  • Schneiderman Daniel H — A-Award (1129323 shares) on 2026-05-01
  • Krishnan Kartik — A-Award (1129323 shares) on 2026-05-01

Open Pasithea Therapeutics Corp. (KTTA) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.